Back to Search Start Over

Vaccination with human anti-trastuzumab anti-idiotype scFv reverses HER2 immunological tolerance and induces tumor immunity in MMTV.f.huHER2(Fo5) mice.

Authors :
Ladjemi, Maha Z
Chardes, Thierry
Corgnac, Stephanie
Garambois, Veronique
Morisseau, Sebastien
Robert, Bruno
Bascoul-Mollevi, Caroline
Ait Arsa, Imade
Jacot, William
Pouget, Jean-Pierre
Pelegrin, Andre
Navarro-Teulon, Isabelle
Ladjemi, Maha Z
Chardes, Thierry
Corgnac, Stephanie
Garambois, Veronique
Morisseau, Sebastien
Robert, Bruno
Bascoul-Mollevi, Caroline
Ait Arsa, Imade
Jacot, William
Pouget, Jean-Pierre
Pelegrin, Andre
Navarro-Teulon, Isabelle
Source :
Breast cancer research : BCR, Vol. 13, no.1, p. R17 (2011)
Publication Year :
2011

Abstract

Anti-trastuzumab anti-Id scFv69, used as a therapeutic or prophylactic vaccine, protects mice from developing HER2-positive mammary tumors by inducing both anti-HER2 Ab1' antibody production and an anti-HER2 Th2-dependent immune response. These results suggest that scFv69 could be used as an anti-Id-based vaccine for adjuvant therapy of patients with HER2-positive tumors to reverse immunological tolerance to HER2.

Details

Database :
OAIster
Journal :
Breast cancer research : BCR, Vol. 13, no.1, p. R17 (2011)
Notes :
English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1104532968
Document Type :
Electronic Resource